RU96105032A - CELL IMMUNITY SWITCHING BY RECEPTIVE CHIMERS - Google Patents

CELL IMMUNITY SWITCHING BY RECEPTIVE CHIMERS

Info

Publication number
RU96105032A
RU96105032A RU96105032/13A RU96105032A RU96105032A RU 96105032 A RU96105032 A RU 96105032A RU 96105032/13 A RU96105032/13 A RU 96105032/13A RU 96105032 A RU96105032 A RU 96105032A RU 96105032 A RU96105032 A RU 96105032A
Authority
RU
Russia
Prior art keywords
cell
target
receptor
protein tyrosine
tyrosine kinase
Prior art date
Application number
RU96105032/13A
Other languages
Russian (ru)
Other versions
RU2158305C2 (en
Inventor
Сид Брайан
Ромео Чарльз
Коланус Вальдемар
Original Assignee
Дзе Дженерал Хоспитал Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Дженерал Хоспитал Корпорейшн filed Critical Дзе Дженерал Хоспитал Корпорейшн
Publication of RU96105032A publication Critical patent/RU96105032A/en
Application granted granted Critical
Publication of RU2158305C2 publication Critical patent/RU2158305C2/en

Links

Claims (16)

1. Клетка, экспрессирующая связанный с мембраной белковый химерный рецептор и включающая в себя (a) внутриклеточную часть протеин-тирозин-киназы, способную передавать сигнал указанной терапевтической клетке на разрушение связанной с рецептором клетки-мишени или связанного с рецептором инфекционного агента-мишени, и (b) внеклеточную часть, способную специфически распознавать указанную клетку-мишень или указанный инфекционный агент-мишень и связывать с ними, в результате чего каждая из указанных терапевтических клеток способна специфически распознавать и разрушать указанную клетку-мишень или указанный инфекционный агент-мишень.1. A cell expressing a membrane-bound protein chimeric receptor and comprising (a) an intracellular portion of a protein tyrosine kinase capable of signaling said therapeutic cell to destroy a target cell or receptor-associated infectious target agent, and (b) an extracellular portion capable of specifically recognizing and binding to said target cell or said target infectious agent, whereby each of said therapeutic cells is capable of specific recognize and destroy said target cell or said target infectious agent. 2. Клетка по п.1, где указанной протеин-тирозин-киназой является член киназного семейства Syk. 2. The cell of claim 1, wherein said tyrosine kinase protein is a member of the Syk kinase family. 3. Клетка по п.2, где указанной протеин-тирозин-киназой является Syk. 3. The cell according to claim 2, where the specified protein tyrosine kinase is Syk. 4. Клетка по п.3, где указанная внутриклеточная часть включает в себя аминокислоты 336-628 Syk человека или аминокислоты 338-630 Syk свиньи. 4. The cell according to claim 3, where the specified intracellular part includes amino acids 336-628 human Syk or amino acids 338-630 Syk pig. 5. Клетка по п.1, где каждая из указанных терапевтических клеток экспрессирует второй, связанный с мембраной, белковый химерный рецептор, причем указанный второй химерный рецептор включает в себя (a) внутриклеточную часть второй протеин-тирозин-киназы, способной передавать сигнал указанной терапевтической клетке на разрушение связанной с рецептором клетки-мишени или связанного с рецептором инфекционного агента-мишени, и (b) внеклеточную часть, способную специфически распознавать указанную клетку-мишень или указанный инфекционный агент-мишень, и связываться с ними, в результате чего каждая из указанных терапевтических клеток способна специфически распознавать и разрушать клетку-мишень или инфекционный агент-мишень. 5. The cell according to claim 1, where each of these therapeutic cells expresses a second membrane-bound protein chimeric receptor, said second chimeric receptor comprising (a) an intracellular portion of a second protein tyrosine kinase capable of signaling said therapeutic a cell to destroy a target cell associated with a receptor or a target infectious agent associated with a receptor, and (b) an extracellular portion capable of specifically recognizing said target cell or said infectious agent and contact them, as a result of which each of the indicated therapeutic cells is capable of specifically recognizing and destroying the target cell or target infectious agent. 6. Клетка по п.5, где одна из указанных протеин-тирозин-киназ является членом киназного семейства Syk, а другая указанная протеин-тирозин-киназа является членом киназного семейства Src. 6. The cell of claim 5, wherein one of said protein tyrosine kinases is a member of the Syk kinase family, and the other said tyrosine kinase protein is a member of the Src kinase family. 7. Клетка по п.6, где одной из указанных протеин-тирозин-киназ является ZAP-70, а другой указанной протеин-тирозин-киназой является Fyn. 7. The cell according to claim 6, where one of these protein tyrosine kinases is ZAP-70, and the other specified protein tyrosine kinase is Fyn. 8. Клетка по п.6, где одной из указанных протеин-тирозин-киназ является ZAP-70, а другой указанной протеин-тирозин-киназой является Lck. 8. The cell according to claim 6, where one of these protein tyrosine kinases is ZAP-70, and the other specified protein tyrosine kinase is Lck. 9. Клетка по п.7 или 8, где указанная ZAP-70-часть содержит Tyr 369 ZAP-70 человека. 9. The cell according to claim 7 or 8, where the specified ZAP-70 part contains Tyr 369 ZAP-70 person. 10. Клетка по п.1 или 5, где указанные терапевтические клетки выбирают из группы, состоящей из (a) T-лимфоцитов; (b) цитотоксических T-лимфоцитов; (c) натуральных клеток-киллеров; (d) нейтрофилов; (e) гранулоцитов; (f) макрофагов; (g) тучных клеток; (h) Hel a-клеток и (i) эмбриональных стволовых клеток (ES). 10. The cell according to claim 1 or 5, where these therapeutic cells are selected from the group consisting of (a) T-lymphocytes; (b) cytotoxic T lymphocytes; (c) natural killer cells; (d) neutrophils; (e) granulocytes; (f) macrophages; (g) mast cells; (h) Hel a-cells; and (i) embryonic stem cells (ES). 11. Клетка по п.1, где указанным инфекционным агентом-мишенью является вирус иммунодефицита. 11. The cell of claim 1, wherein said target infectious agent is an immunodeficiency virus. 12. Клетка по п. 11, где указанная внеклеточная часть включает в себя часть CD4, связывающуюся с оболочкой вируса ВИЧ. 12. The cell of claim 11, wherein said extracellular portion includes a portion of CD4 that binds to the envelope of the HIV virus. 13. Клетка по п.1 или 5, где указанное связывание является МНС-независимым. 13. The cell according to claim 1 or 5, where the specified binding is MHC-independent. 14. Клетка по п. 1 или 5, где указанная внеклеточная часть включает в себя лиганд-связывающую часть рецептора, рецептор-связывающую часть лиганда, антиген-связывающую часть антитела, или их функциональное производное. 14. The cell of claim 1 or 5, wherein said extracellular portion includes a ligand-binding portion of a receptor, a receptor-binding portion of a ligand, an antigen-binding portion of an antibody, or a functional derivative thereof. 15. ДНК, кодирующая химерный рецептор по п.1 или 5. 15. DNA encoding a chimeric receptor according to claim 1 or 5. 16. Вектор, включающий в себя ДНК химерного рецептора по п.1 или 5. 16. A vector comprising the DNA of a chimeric receptor according to claim 1 or 5.
RU96105032/13A 1993-07-16 1994-06-14 Protein chimeric receptor, dna encoding protein chimeric receptor RU2158305C2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9321093A 1993-07-16 1993-07-16
US08/093210 1993-07-16

Publications (2)

Publication Number Publication Date
RU96105032A true RU96105032A (en) 1998-05-27
RU2158305C2 RU2158305C2 (en) 2000-10-27

Family

ID=22237762

Family Applications (1)

Application Number Title Priority Date Filing Date
RU96105032/13A RU2158305C2 (en) 1993-07-16 1994-06-14 Protein chimeric receptor, dna encoding protein chimeric receptor

Country Status (18)

Country Link
EP (1) EP0804552B1 (en)
JP (2) JP3588115B2 (en)
KR (1) KR100278352B1 (en)
AT (1) ATE236973T1 (en)
AU (2) AU686646B2 (en)
CA (1) CA2166102C (en)
CZ (1) CZ291754B6 (en)
DE (1) DE69432487T2 (en)
DK (1) DK0804552T3 (en)
ES (1) ES2197166T3 (en)
FI (1) FI119995B (en)
HU (1) HU224137B1 (en)
NO (1) NO316942B1 (en)
NZ (1) NZ269312A (en)
PT (1) PT804552E (en)
RU (1) RU2158305C2 (en)
WO (1) WO1995002686A1 (en)
ZA (1) ZA945204B (en)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6407221B1 (en) 1990-12-14 2002-06-18 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US6319494B1 (en) 1990-12-14 2001-11-20 Cell Genesys, Inc. Chimeric chains for receptor-associated signal transduction pathways
US6753162B1 (en) 1991-03-07 2004-06-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US6004811A (en) 1991-03-07 1999-12-21 The Massachussetts General Hospital Redirection of cellular immunity by protein tyrosine kinase chimeras
US5851828A (en) 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
US7049136B2 (en) 1991-03-07 2006-05-23 The General Hospital Corporation Redirection of cellular immunity by receptor chimeras
US5912170A (en) 1991-03-07 1999-06-15 The General Hospital Corporation Redirection of cellular immunity by protein-tyrosine kinase chimeras
US6077947A (en) * 1995-02-02 2000-06-20 Cell Genesys, Inc. DNA encoding an intracellular chimeric receptor comprising Janus kinase
US6103521A (en) * 1995-02-06 2000-08-15 Cell Genesys, Inc. Multispecific chimeric receptors
GB9526131D0 (en) * 1995-12-21 1996-02-21 Celltech Therapeutics Ltd Recombinant chimeric receptors
US5916771A (en) * 1996-10-11 1999-06-29 Abgenix, Inc. Production of a multimeric protein by cell fusion method
US6420140B1 (en) 1996-10-11 2002-07-16 Abgenix, Inc. Production of multimeric protein by cell fusion method
GB9809658D0 (en) * 1998-05-06 1998-07-01 Celltech Therapeutics Ltd Biological products
UY34807A (en) 2012-05-16 2013-12-31 Novartis Ag MONOCYCLIC DERIVATIVES OF HETEROARYL CYCLOALKYL-DIAMINE
KR20200130709A (en) 2018-03-06 2020-11-19 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 Prostate-specific membrane antigen CAR and methods of use thereof

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5851828A (en) * 1991-03-07 1998-12-22 The General Hospital Corporation Targeted cytolysis of HIV-infected cells by chimeric CD4 receptor-bearing cells
IE920716A1 (en) * 1991-03-07 1992-09-09 Gen Hospital Corp Redirection of cellular immunity by receptor chimeras

Similar Documents

Publication Publication Date Title
CA2209301A1 (en) Redirection of cellular immunity by protein-tyrosine kinase chimeras
RU97115895A (en) CELL IMMUNITY SWITCHING USED BY TYROSINE-SPECIFIC PROTEINKINASE CHEMERS
RU96105032A (en) CELL IMMUNITY SWITCHING BY RECEPTIVE CHIMERS
CA2209300A1 (en) Redirection of cellular immunity by receptor chimeras
Letourneur et al. Characterization of the family of dimers associated with Fc receptors (Fc epsilon RI and Fc gamma RIII).
RU97115769A (en) REDIRECTION OF CELL IMMUNITY BY CHIMERIC RECEPTORS
Chaudhary et al. Selective killing of HIV-infected cells by recombinant human CD4-Pseudomonas exotoxin hybrid protein
KR970701004A (en) Targeting Cytolysis of HIV Infected Cells by Chimeric CD4 Receptor-Containing Cells
Stamenkovic et al. The B-cell antigen CD22 mediates monocyte and erythrocyte adhesion
Curtis et al. Sequence and expression of a membrane-associated C-type lectin that exhibits CD4-independent binding of human immunodeficiency virus envelope glycoprotein gp120.
Jones et al. Heparan sulfate proteoglycans mediate attachment and entry of human T-cell leukemia virus type 1 virions into CD4+ T cells
Meyer et al. Nuclear transport of human immunodeficiency virus type 1, visna virus, and equine infectious anemia virus Rev proteins: identification of a family of transferable nuclear export signals
UA41870C2 (en) method for direction of cell response TOWARDS infection agent, cell, infected with the said agent, tumor, malignant cell or autoimmune cell (variants), cell expressing membrane-tied protein chimeric receptor (variants), DNA coding chimeric receptor, vector, a method for the treatment of infection of immunodeficiency virus (variants)
Mondor et al. Interactions among HIV gp120, CD4, and CXCR4: dependence on CD4 expression level, gp120 viral origin, conservation of the gp120 COOH-and NH2-termini and V1/V2 and V3 loops, and sensitivity to neutralizing antibodies
EP1489099A3 (en) Antibodies that bind the CD40CR receptor
FI894065A (en) HUMANRHINOVIRUSRECEPTORPROTEIN SOM HAEMMAR INFEKTIONSFOERMAOGAN HOS VIRUS.
Morikawa et al. Expression of HIV-1 gp120 and human soluble CD4 by recombinant baculoviruses and their interaction in vitro
Zhou et al. Cells transfected with a non-neutralizing antibody gene are resistant to HIV infection: targeting the endoplasmic reticulum and trans-Golgi network
KR100585246B1 (en) Cd8 as an inhibitor of the cellular immune system
DK258789D0 (en) PEPTIDES THAT BLOCK THE BINDING OF HIV-1 TO THE CD4 RECEPTOR PROTEIN
McDougal et al. CD4—gp120 interactions
Harrison CD4: Structure and interactions of an immunoglobulin superfamily adhesion molecule
MY131433A (en) Novel metazoan parasite antigens having pepstatin binding activity and their use in vaccines
Kaneko et al. Human immunodeficiency virus type 2 envelope glycoprotein binds to CD8 as well as to CD4 molecules on human T cells
EA200200598A1 (en) GENE THERAPY OF HIV-INFECTED BY EXPRESSION OF GP41 ANIMATED ON MEMBRANE PEPTED